Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

3 results
6:24 PM, Jan 27, 2016  |  BC Extra | Company News

Merck, CRT in deal for PRMT5 inhibitors

including the epigenetic control of p53 and other genes. It is one of over 20 histone methyltransferases
6:02 PM, Apr 26, 2012  |  BC Extra | Company News

Celgene, Epizyme in epigenetic deal

partnered with Epizyme Inc. (Cambridge, Mass.) to discover, develop and commercialize cancer therapeutics that inhibit histone methyltransferases
for an initial three years, with a potential one-year extension. The deal does not include histone methyltransferases
months. In January 2011, Epizyme partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for therapeutics targeting undisclosed histone methyltransferases
6:24 PM, Jan 10, 2011  |  BC Extra | Company News

GSK, Epizyme in histone methyltransferases deal

partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases